Jyoti Nangalia

22.6k total citations · 1 hit paper
48 papers, 1.7k citations indexed

About

Jyoti Nangalia is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Jyoti Nangalia has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 31 papers in Hematology and 25 papers in Molecular Biology. Recurrent topics in Jyoti Nangalia's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Acute Myeloid Leukemia Research (21 papers) and Kruppel-like factors research (15 papers). Jyoti Nangalia is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Acute Myeloid Leukemia Research (21 papers) and Kruppel-like factors research (15 papers). Jyoti Nangalia collaborates with scholars based in United Kingdom, United States and Italy. Jyoti Nangalia's co-authors include Anthony R. Green, Peter J. Campbell, Anna L. Godfrey, Jacob Grinfeld, Claire Harrison, Emily Mitchell, Nicholas Williams, Adam J. Mead, Alessandro M. Vannucchi and Luiza Moore and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Jyoti Nangalia

46 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Life histories of myeloproliferative neoplasms inferred from phylogenies.

2022 148 citations Nicholas Williams, Joe Lee et al. Apollo (University of Cambridge) profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jyoti Nangalia United Kingdom	24	1.1k	993	830	399	217	48	1.7k
Éric Lippert France	23	1.4k 1.3×	1.3k 1.3×	968 1.2×	603 1.5×	98 0.5×	102	2.2k
Jean-Luc Laı̈ France	14	715 0.7×	1.1k 1.2×	605 0.7×	297 0.7×	94 0.4×	33	1.4k
Giovanna Rege‐Cambrin Italy	21	893 0.8×	1.4k 1.4×	612 0.7×	352 0.9×	130 0.6×	70	2.0k
Lydia Roy France	22	1.1k 1.0×	1.4k 1.4×	551 0.7×	719 1.8×	89 0.4×	65	2.1k
Olivier Kosmider France	26	1.0k 0.9×	1.6k 1.6×	1.2k 1.5×	236 0.6×	294 1.4×	107	2.5k
Eva Hellström‐Lindberg Sweden	20	758 0.7×	1.5k 1.5×	855 1.0×	89 0.2×	156 0.7×	29	1.9k
J V Melo United Kingdom	17	644 0.6×	839 0.8×	440 0.5×	390 1.0×	135 0.6×	27	1.3k
Nathalie Grardel France	15	591 0.5×	848 0.9×	322 0.4×	250 0.6×	117 0.5×	40	1.3k
Ya‐Zhen Qin China	23	472 0.4×	1.5k 1.5×	503 0.6×	172 0.4×	107 0.5×	153	1.9k
Sandra Moore United States	9	1.3k 1.2×	1.1k 1.1×	978 1.2×	445 1.1×	41 0.2×	11	1.7k

Countries citing papers authored by Jyoti Nangalia

Since Specialization

Citations

This map shows the geographic impact of Jyoti Nangalia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jyoti Nangalia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jyoti Nangalia more than expected).

Fields of papers citing papers by Jyoti Nangalia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jyoti Nangalia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jyoti Nangalia. The network helps show where Jyoti Nangalia may publish in the future.

Co-authorship network of co-authors of Jyoti Nangalia

This figure shows the co-authorship network connecting the top 25 collaborators of Jyoti Nangalia. A scholar is included among the top collaborators of Jyoti Nangalia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jyoti Nangalia. Jyoti Nangalia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Godfrey, Anna L., Andrew McGregor, Andrew J. Innes, et al.. (2025). Investigation and management of thrombocytosis without JAK2 , CALR or MPL mutations: A British Society for Haematology Guideline. British Journal of Haematology. 208(2). 471–485.

Leongamornlert, Daniel, Nicholas Williams, Xin Wang, et al.. (2025). Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia. Nature. 640(8060). 982–990. 2 indexed citations

Zhao, Jiawei, Liam D. Cato, Erik L. Bao, et al.. (2024). Inherited blood cancer predisposition through altered transcription elongation. Cell. 187(3). 642–658.e19. 13 indexed citations

Bernstein, Nicholas, Michael Spencer Chapman, Nicholas Williams, et al.. (2024). Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis. Nature Genetics. 56(6). 1147–1155. 36 indexed citations

Guo, Jing, Klaudia Walter, Pedro M. Quirós, et al.. (2024). Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms. Nature Genetics. 56(2). 273–280. 10 indexed citations

Chapman, Michael Spencer, Alyssa Cull, Marioara F. Ciuculescu, et al.. (2023). Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease. Nature Medicine. 29(12). 3175–3183. 27 indexed citations

Williams, Nicholas, Joe Lee, Emily Mitchell, et al.. (2022). Life histories of myeloproliferative neoplasms inferred from phylogenies.. Apollo (University of Cambridge). 148 indexed citations breakdown →

Chapman, Michael Spencer, Anna Maria Ranzoni, Brynelle Myers, et al.. (2021). Lineage tracing of human development through somatic mutations. Nature. 595(7865). 85–90. 84 indexed citations

Coorens, Tim, Grace Collord, Emily Mitchell, et al.. (2021). Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. Blood. 137(21). 2992–2997. 17 indexed citations

10.

Álvarez‐Larrán, Alberto, Emanuela Sant’Antonio, Claire Harrison, et al.. (2021). Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. The Lancet Haematology. 8(9). e658–e665. 17 indexed citations

11.

Lee, Joe, Anna L. Godfrey, & Jyoti Nangalia. (2020). Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. Blood Reviews. 42. 100708–100708. 10 indexed citations

12.

Øbro, Nina Friesgaard, Jacob Grinfeld, Miriam Belmonte, et al.. (2020). Longitudinal Cytokine Profiling Identifies GRO‐α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia. HemaSphere. 4(3). e371–e371. 39 indexed citations

13.

McMullin, Mary Frances, Adam J. Mead, Sahra Ali, et al.. (2018). A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. British Journal of Haematology. 184(2). 161–175. 70 indexed citations

14.

McMullin, Mary Frances, Claire Harrison, Catherine Cargo, et al.. (2018). A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology. 184(2). 176–191. 94 indexed citations

15.

Godfrey, Anna L., Peter J. Campbell, Cathy MacLean, et al.. (2018). Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. Journal of Clinical Oncology. 36(34). 3361–3369. 49 indexed citations

16.

Godfrey, Anna L., Peter J. Campbell, Cathy MacLean, et al.. (2017). Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial. Blood. 130. 319–319.

17.

Mesa, Ruben A., Miklós Egyed, Anita Szőke, et al.. (2016). Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.. Journal of Clinical Oncology. 34(15_suppl). 7065–7065. 7 indexed citations

18.

Fuller, Kathryn A., Jyoti Nangalia, Katie Meehan, et al.. (2015). Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms. Journal of Clinical Pathology. 69(2). 155–163. 20 indexed citations

19.

Li, Juan, David G. Kent, Anna L. Godfrey, et al.. (2014). JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood. 123(20). 3139–3151. 55 indexed citations

20.

Jones, Amy V., Daniel Ward, Matthew Lyon, et al.. (2014). Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leukemia Research. 39(1). 82–87. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact